8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Apr 21, 2011)

Filed April 21, 2011For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on April 21, 2011, primarily to furnish a press release detailing its financial results for the three months ended March 31, 2011. This filing is crucial for investors seeking to understand the company's recent performance and financial standing. The press release, attached as Exhibit 99, contains the operational and financial data for the first quarter of 2011. While the 8-K itself does not disclose the specific financial figures, it directs investors to the furnished press release for details on revenue, profitability, and other key performance indicators. This is a standard practice for announcing quarterly earnings, allowing for a more comprehensive and immediate dissemination of financial information to the market. Investors should review Exhibit 99 for the actual financial results and any management commentary provided therein.

Key Highlights

  • 1Biogen Idec announced its Q1 2011 financial results via a press release.
  • 2The press release is furnished as Exhibit 99 to the 8-K filing.
  • 3The filing serves as notification to the market of the company's financial performance for the quarter ended March 31, 2011.
  • 4Information on operations and financial condition for the period is contained within the press release.
  • 5The press release is not deemed 'filed' under Section 18 of the Exchange Act, limiting its liability exposure.
  • 6This filing is a procedural step to incorporate the earnings release into public record.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and furnish Biogen Idec's press release containing its financial results and operational performance for the three months ended March 31, 2011.

The actual financial results for the quarter ended March 31, 2011, are detailed in the press release furnished as Exhibit 99 to this 8-K filing. Investors should refer to Exhibit 99 for specific figures on revenue, earnings, and other financial metrics.

No, the press release is furnished pursuant to Item 2.02 of the Current Report. It is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor is it incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act.

The 8-K filing was signed by Robert A. Licht, Senior Vice President, on behalf of Biogen Idec Inc.